| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | ERG1, HERG, LQT2, SQT1, HERG1, Kv11.1 |
| WB Predicted band size | 90 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human KCNH2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是模拟生成的关于KCNH2抗体的参考文献示例(仅供学术参考，具体文献需通过数据库验证)：
---
1. **文献名称**：*Characterization of KCNH2 (HERG) Protein Expression in Human Cardiomyocytes Using a Novel Monoclonal Antibody*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种特异性抗KCNH2的单克隆抗体，并通过Western blot和免疫荧光技术验证其在人心肌细胞中的表达。结果显示该抗体能有效检测HERG通道蛋白，并在长QT综合征患者心肌样本中发现表达水平下降。
2. **文献名称**：*Immunolocalization of KCNH2 in Cardiac Tissue: Implications for Arrhythmia Pathogenesis*
**作者**：Jones B, et al.
**摘要**：利用兔多克隆KCNH2抗体，研究者通过免疫组化技术揭示了HERG蛋白在心脏传导系统中的分布特征，发现其在心室肌细胞膜上的表达异常与遗传性心律失常相关。
3. **文献名称**：*Development and Validation of a KCNH2-Specific Antibody for Functional Studies in Heterologous Expression Systems*
**作者**：Chen L, et al.
**摘要**：本研究报道了一种高亲和力KCNH2抗体的开发，用于检测HEK293细胞中过表达的HERG通道。抗体验证显示其适用于流式细胞术和共聚焦显微镜，为药物筛选提供了工具。
4. **文献名称**：*Altered KCNH2 Expression in Zebrafish Models of Long QT Syndrome: Insights from Antibody-Based Assays*
**作者**：Wang X, et al.
**摘要**：通过斑马鱼长QT综合征模型，研究者使用抗KCNH2抗体进行蛋白定量分析，发现突变型HERG的降解加速现象，提示泛素-蛋白酶体系统可能参与疾病机制。
---
**提示**：实际文献需通过PubMed、Google Scholar等平台检索关键词(如“KCNH2 antibody”、“HERG antibody application”)。建议结合研究目的筛选特定实验场景(如Western blot、免疫组化)的相关论文。
The KCNH2 antibody is a crucial tool in cardiovascular research, targeting the KCNH2 protein encoded by the *KCNH2* gene (also known as *hERG*). This voltage-gated potassium channel, primarily expressed in cardiac tissue, plays a pivotal role in repolarizing cardiac action potentials by mediating the rapid delayed rectifier potassium current (\(I_{Kr}\)). Dysfunction of KCNH2. often due to genetic mutations or drug-induced inhibition, is linked to life-threatening arrhythmias such as long QT syndrome type 2 (LQT2) and sudden cardiac death.
KCNH2 antibodies are widely used to investigate channel expression, localization, and trafficking in both physiological and pathological contexts. They enable detection of KCNH2 via techniques like Western blot, immunohistochemistry, and immunofluorescence, aiding studies on channel assembly, post-translational modifications, and interactions with regulatory proteins. Commercially available antibodies are typically raised against specific epitopes, such as intracellular N- or C-terminal domains, with validation in human, rodent, or other model systems.
Research applications extend to drug safety assessments, as many pharmaceuticals unintentionally block KCNH2. prolonging QT intervals. Additionally, these antibodies support diagnostic workflows for genetic screening in familial arrhythmia syndromes. Recent advances also explore KCNH2's roles beyond the heart, including neuronal and cancer biology. However, users must verify antibody specificity due to potential cross-reactivity with related potassium channels or splice variants. Overall, KCNH2 antibodies remain indispensable for unraveling cardiac electrophysiology and developing targeted therapies.
×
